The Biotech is pretty flat in the last 7 days, but Innovent Biologics has stood out, gaining 6.1%. As for the longer term, the industry has declined 29% in the last year. As for the next few years, earnings are expected to grow by 34% per annum.
Has the Hong Kong Biotech Industry valuation changed over the past few years?
Date | Market Cap | Revenue | Earnings | PE | Absolute PE | PS |
---|---|---|---|---|---|---|
Mon, 12 Aug 2024 | HK$324.3b | HK$50.2b | -HK$19,689,126,009.11 | 11.6x | -16.5x | 6.5x |
Wed, 10 Jul 2024 | HK$311.3b | HK$49.6b | -HK$19,438,925,922.83 | 12x | -16x | 6.3x |
Fri, 07 Jun 2024 | HK$346.8b | HK$49.8b | -HK$19,505,287,469.59 | 12.1x | -17.8x | 7x |
Sun, 05 May 2024 | HK$371.6b | HK$49.8b | -HK$19,209,646,888.34 | 12.4x | -19.3x | 7.5x |
Tue, 02 Apr 2024 | HK$342.6b | HK$49.5b | -HK$19,402,792,136.08 | 12.5x | -17.7x | 6.9x |
Thu, 29 Feb 2024 | HK$347.3b | HK$47.2b | -HK$20,397,339,034.63 | 15.8x | -17x | 7.4x |
Sat, 27 Jan 2024 | HK$325.4b | HK$47.1b | -HK$20,321,469,234.00 | 16.1x | -16x | 6.9x |
Mon, 25 Dec 2023 | HK$386.8b | HK$47.1b | -HK$20,319,677,740.00 | 16.4x | -19x | 8.2x |
Wed, 22 Nov 2023 | HK$412.3b | HK$46.3b | -HK$18,626,654,781.00 | 18.8x | -22.1x | 8.9x |
Fri, 20 Oct 2023 | HK$378.8b | HK$44.9b | -HK$19,085,283,244.00 | 12.6x | -19.8x | 8.4x |
Sun, 17 Sep 2023 | HK$413.8b | HK$45.1b | -HK$18,990,713,694.00 | 15.5x | -21.8x | 9.2x |
Tue, 15 Aug 2023 | HK$382.3b | HK$35.4b | -HK$23,150,356,138.00 | 25.3x | -16.5x | 10.8x |
Thu, 13 Jul 2023 | HK$403.8b | HK$35.5b | -HK$23,353,465,547.00 | 25.3x | -17.3x | 11.4x |
Sat, 10 Jun 2023 | HK$407.2b | HK$35.8b | -HK$23,572,708,139.00 | 26.6x | -17.3x | 11.4x |
Mon, 08 May 2023 | HK$452.8b | HK$36.7b | -HK$24,346,812,406.00 | 16.5x | -18.6x | 12.4x |
Wed, 05 Apr 2023 | HK$423.1b | HK$36.0b | -HK$24,278,814,691.00 | 12.2x | -17.4x | 11.7x |
Fri, 03 Mar 2023 | HK$410.8b | HK$33.3b | -HK$36,194,359,868.00 | 25.5x | -11.3x | 12.3x |
Sun, 29 Jan 2023 | HK$467.1b | HK$34.9b | -HK$35,242,741,407.00 | 31.3x | -13.3x | 13.4x |
Tue, 27 Dec 2022 | HK$388.0b | HK$33.7b | -HK$33,948,658,471.00 | 23.1x | -11.4x | 11.5x |
Thu, 24 Nov 2022 | HK$352.3b | HK$33.1b | -HK$33,281,981,877.00 | 21.2x | -10.6x | 10.7x |
Sat, 22 Oct 2022 | HK$324.5b | HK$33.7b | -HK$32,118,113,104.00 | 16.6x | -10.1x | 9.6x |
Mon, 19 Sep 2022 | HK$315.6b | HK$34.2b | -HK$33,501,064,041.00 | 20.7x | -9.4x | 9.2x |
Wed, 17 Aug 2022 | HK$335.0b | HK$32.8b | -HK$46,025,407,450.00 | 12.1x | -7.3x | 10.2x |
Fri, 15 Jul 2022 | HK$365.0b | HK$33.0b | -HK$46,533,006,363.00 | 14x | -7.8x | 11.1x |
Sun, 12 Jun 2022 | HK$357.2b | HK$33.0b | -HK$46,592,039,317.00 | 14.7x | -7.7x | 10.8x |
Tue, 10 May 2022 | HK$314.0b | HK$34.2b | -HK$45,397,203,424.00 | 12.8x | -6.9x | 9.2x |
Thu, 07 Apr 2022 | HK$372.3b | HK$36.4b | -HK$46,242,884,784.00 | 14.7x | -8.1x | 10.2x |
Sat, 05 Mar 2022 | HK$326.8b | HK$34.0b | -HK$31,239,577,575.00 | 13.7x | -10.5x | 9.6x |
Mon, 31 Jan 2022 | HK$293.1b | HK$31.1b | -HK$31,841,442,755.00 | 11.3x | -9.2x | 9.4x |
Wed, 29 Dec 2021 | HK$379.2b | HK$31.1b | -HK$31,826,765,471.00 | 13.2x | -11.9x | 12.2x |
Fri, 26 Nov 2021 | HK$516.9b | HK$31.0b | -HK$31,721,285,866.00 | 13.7x | -16.3x | 16.7x |
Sun, 24 Oct 2021 | HK$492.3b | HK$30.7b | -HK$31,774,543,189.00 | 15.3x | -15.5x | 16x |
Tue, 21 Sep 2021 | HK$521.3b | HK$30.4b | -HK$31,436,180,691.00 | 16.5x | -16.6x | 17.1x |
Thu, 19 Aug 2021 | HK$514.0b | HK$30.2b | -HK$32,058,827,347.35 | 15.1x | -16x | 17x |
-16x
Which industries have driven the changes within the Hong Kong Healthcare industry?
HK Market | -0.15% | |
Healthcare | 2.24% | |
Biotech | 0.83% | |
Biotech | 0.83% |
Which companies have driven the market over the last 7 days?
Company | Last Price | 7D | 1Y | Valuation | |
---|---|---|---|---|---|
1801 Innovent Biologics | HK$41.65 | 6.1% +HK$3.9b | 25.6% | PS10x | |
9926 Akeso | HK$43.80 | 4.3% +HK$1.6b | 30.6% | PE17.2x | |
2162 Keymed Biosciences | HK$33.65 | 4.2% +HK$373.4m | -26.8% | PS24.2x | |
6855 Ascentage Pharma Group International | HK$28.60 | 4.2% +HK$355.5m | 3.4% | PS36.6x | |
6990 Sichuan Kelun-Biotech Biopharmaceutical | HK$156.00 | 0.9% +HK$312.0m | 102.1% | PS20.7x |